A shift is in the air at SXSWh
Posted 5th April 2012 in Articles, Conferences, General | Register to comment
Continuing his lively overview of SXSW, Joe shares his views on the final health sessions of the event.
The streets filled up with skinny jeans and there were fewer plaid shirts as SXSW Interactive began making way for the world-famous…
Read the full articleThe sun (finally) shines upon SXSWh
Posted 29th March 2012 in Articles, Conferences, General | Register to comment
In part one of a two-part article, Joe Doyle reports from the health sessions at South by Southwest.
The first three days of South by Southwest (“South By”) were a whirlwind of education, elbow-rubbing, detailing and parties. But until…
Read the full articleBiosimilars 2012 – what does the current landscape look like?
Posted 8th March 2012 in Articles, Conferences, General | Register to comment
Rebecca Aris reports from the Biosimilars Congregation 2012 on the latest trends in this space.
Biologic treatments have revolutionised medicine and, following in their footsteps, biosimilars are set to continue the…
Read the full articleThe pharma summit 2012 – finding new directions
Posted 22nd February 2012 in Articles, Conferences, General | Register to comment
Rebecca Aris gives an overview of the topics discussed at the recent Economist conference ‘The pharma summit 2012 – finding new directions’.
R&D costs are increasing facing pharma with, according to the media, a ‘perfect storm’ resulting in a need to find a new direction for…
Read the full articlePublication of clinical trial data: enough of the excuses!
Posted 29th November 2011 in Articles, Conferences, General | Register to comment
How much negative data goes unpublished? Ryan Woodrow set to find out and his surprising results are detailed here.
I attended a MedComms Networking event last summer to listen to the thoughts of Ben Goldacre on the pharmaceutical industry. For those of you who…
Read the full articleNovelty and hope make news at the ACR scientific meeting
Posted 25th November 2011 in Articles, Conferences, Therapeutic Area | 1 comment
Kelly Young, RA patient, reports from the 75th annual American College of Rheumatology (ACR) Scientific Meeting.
Over 16,000 people attended the recent 75th annual American College of Rheumatology (ACR) Scientific Meeting in Chicago …
Read the full articleCan increased transparency lead to trust in the industry?
Posted 22nd September 2011 in Articles, Conferences | Register to comment
pharmaphorum reports on the recent Strategic MedComms Forum 2011 to find out steps we can take to increase transparency and trust in the industry.
Trust in the pharmaceutical industry in clearly lacking. Given that trust in pharma contributes hugely to public health, this is a…
Read the full articleTunnah’s musings: what’s in it for me?
Posted 16th September 2011 in Articles, Conferences | Register to comment
Inspired by the discussion from the recent healthcare social media global camp, Paul Tunnah asks if we need to be more selfish to produce game-changing healthcare solutions.
At the heart of it we’re all selfish creatures, we’re all driven by our own internal desires. Don’t worry – this is not going to be a rant on humanity, but it is…
Read the full articleDelivering medicines of value in an age of cost containment
Posted 13th September 2011 in Articles, Conferences, Interviews | Register to comment
Everyone wants more for less in the current climate. pharmaphorum speaks to Rick Morton, of PAREXEL, to find out how pharma can meet the challenge of delivering real value.
It’s not just within the pharma industry that the term “value” is being thrown around – given the current economic uncertainties companies and consumers in…
Read the full articleValue-based pricing: no place to hide from the payer
Posted 12th September 2011 in Articles, Conferences, Interviews | Register to comment
As the term “value-based pricing” starts to underpin pharma discussions with the payer, pharmaphorum speaks with market access expert Omar Ali to find out what it really means.
The hurdles to ensuring effective market access for new drugs seem to creep ever higher as countries around the world implement stricter cost containment…
Read the full article